Maternal Exposure to Anti-TNF or Thiopurines for IBD Does Not Increase Risk of Early-life Malignancy in Children

Clin Gastroenterol Hepatol. 2023 Sep;21(10):2679-2681.e5. doi: 10.1016/j.cgh.2022.08.028. Epub 2022 Sep 5.

Authors

Antoine Meyer¹, Paula Rios², Jérôme Drouin², Alain Weill², Franck Carbonnel³, Rosemary Dray-Spira²

Affiliations

¹ EPIPHARE, Épidémiologie des Produits de Santé, Saint-Denis, France; Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre & Université Paris Saclay, Le Kremlin Bicêtre, France. Electronic address: antoinemeyer@gmail.com.
² EPIPHARE, Épidémiologie des Produits de Santé, Saint-Denis, France.
³ Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre & Université Paris Saclay, Le Kremlin Bicêtre, France.

PMID: 36064096
DOI: 10.1016/j.cgh.2022.08.028

No abstract available

MeSH terms

Child
Female
Humans
Immunologic Factors
Immunosuppressive Agents
Inflammatory Bowel Diseases* / drug therapy
Maternal Exposure
Neoplasms*
Risk Factors
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha

Substances

Tumor Necrosis Factor Inhibitors
Immunosuppressive Agents
Immunologic Factors
Tumor Necrosis Factor-alpha